Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Remodeling the Bone Marrow Microenvironment – A Proposal for Targeting Pro-inflammatory Contributors in MPN
Jonas S. Jutzi, Ann Mullally
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 20

Showing 20 citing articles:

Mechanical checkpoint regulates monocyte differentiation in fibrotic niches
Kyle H. Vining, Anna E. Marneth, Kwasi Adu‐Berchie, et al.
Nature Materials (2022) Vol. 21, Iss. 8, pp. 939-950
Open Access | Times Cited: 47
Still a burning question: the interplay between inflammation and fibrosis in myeloproliferative neoplasms
Hélène F.E. Gleitz, Adam Benabid, Rebekka K. Schneider
Current Opinion in Hematology (2021) Vol. 28, Iss. 5, pp. 364-371
Open Access | Times Cited: 25
Quantitative interpretation of bone marrow biopsies in MPN—What's the point in a molecular age?
Hosuk Ryou, Oliver Lomas, Helen Theissen, et al.
British Journal of Haematology (2023) Vol. 203, Iss. 4, pp. 523-535
Open Access | Times Cited: 8
The immune landscape in BCR‐ABL negative myeloproliferative neoplasms: inflammation, infections and opportunities for immunotherapy
Marie Strickland, Lynn Quek, Bethan Psaila
British Journal of Haematology (2021) Vol. 196, Iss. 5, pp. 1149-1158
Open Access | Times Cited: 18
Polycythemia vera: past, present and future
Ami B. Patel, Lucia Masárová, Ruben A. Mesa, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2024), pp. 1-13
Closed Access | Times Cited: 2
Oncogenic Calreticulin Induces Immune Escape by Stimulating TGF-β Expression and Regulatory T Cell Expansion in the Bone Marrow Microenvironment
Dominik Schmidt, Cornelia Endres, Rouven Hoefflin, et al.
Cancer Research (2024)
Closed Access | Times Cited: 2
Elevated levels of damage-associated molecular patterns HMGB1 and S100A8/A9 coupled with toll-like receptor-triggered monocyte activation are associated with inflammation in patients with myelofibrosis
Geraldine De Luca, Nora P. Goette, Paola R. Lev, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
The Contemporary Approach to CALR-Positive Myeloproliferative Neoplasms
Tanja Belčič Mikič, Tadej Pajič, Samo Zver, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 7, pp. 3371-3371
Open Access | Times Cited: 13
Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms
Hans Carl Hasselbalch, Peter Junker, Vibe Skov, et al.
Cancers (2023) Vol. 15, Iss. 17, pp. 4323-4323
Open Access | Times Cited: 5
Impact of the rs1024611 Polymorphism of CCL2 on the Pathophysiology and Outcome of Primary Myelofibrosis
Elena Masselli, Cecilia Carubbi, Giulia Pozzi, et al.
Cancers (2021) Vol. 13, Iss. 11, pp. 2552-2552
Open Access | Times Cited: 12
Immune Dysregulation and Infectious Complications in MPN Patients Treated With JAK Inhibitors
Daniele Cattaneo, Alessandra Iurlo
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 11
High cell-free DNA is associated with disease progression, inflammasome activation and elevated levels of inflammasome-related cytokine IL-18 in patients with myelofibrosis
Geraldine De Luca, Paola R. Lev, María Fernanda Camacho, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 4
Anti-inflammatory treatment in MPN: targeting TNFR1 and TNFR2 in JAK2-V617F–induced disease
Peter Müller, Conny K. Baldauf, Tobias R. Haage, et al.
Blood Advances (2021) Vol. 5, Iss. 23, pp. 5349-5359
Open Access | Times Cited: 9
Anti–IL-6 cytokine treatment has no impact on elevated hematocrit or splenomegaly in a polycythemia vera mouse model
Conny K. Baldauf, Peter Müller, Tobias R. Haage, et al.
Blood Advances (2021) Vol. 6, Iss. 2, pp. 399-404
Open Access | Times Cited: 6
PEDF reduces malignant cells proliferation and inhibits the progression of myelofibrosis in myeloproliferative neoplasms
Yanjie Li, Hui Gao, Hongyan Dong, et al.
Biochemical Pharmacology (2022) Vol. 199, pp. 115013-115013
Closed Access | Times Cited: 3
Tracking fibrosis in myeloproliferative neoplasms by CCR2 expression on CD34+ cells
Giulia Pozzi, Cecilia Carubbi, Giuliana Gobbi, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 3
Myeloproliferative Neoplasms Transcriptome Reveals Pro-Inflammatory Signature and Enrichment in Peripheral Blood Monocyte-Related Genes
Vitor Leonardo Bassan, Rafaela de Freitas Martins Felício, Kelen Cristina Ribeiro Malmegrim, et al.
Cancer Investigation (2024) Vol. 42, Iss. 7, pp. 605-618
Closed Access
Shaping the Future of Myeloproliferative Neoplasm Therapy: Immune-Based Strategies and Targeted Innovations
Alberto Carturan, Sonia Morè, Antonella Poloni, et al.
Cancers (2024) Vol. 16, Iss. 23, pp. 4113-4113
Open Access
In the Pipeline: Emerging Therapy for Classical Ph-Negative MPNs
Harinder Gill, Yammy Yung
(2023), pp. 607-623
Closed Access
Non-canonical Hedgehog signaling mediates profibrotic hematopoiesis-stroma crosstalk in myeloproliferative neoplasms
Jessica E. Pritchard, Juliette E. Pearce, Inge Snoeren, et al.
Cell Reports (2023) Vol. 43, Iss. 1, pp. 113608-113608
Open Access
Page 1

Scroll to top